72 research outputs found

    Silicon photonics in Pirelli

    Get PDF
    Silicon is the dominant material in the microelectronic industry and silicon photonics is rapidly gaining importance as a technological platform for a wide range of applications in telecom, and optical interconnect. It allows the implementation of many photonic functions through the use of wafer-scale technologies normally used for advanced CMOS-processing. In this paper some of the most important issues toward a practical implementation of Silicon photonics into an industrial device will be addressed: low loss waveguides, polarization handling, tunability, hitless switching. A tunable Add-Drop multiplexer has been chosen as a case Study of a fully integrated device

    Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.

    Get PDF
    Randomized trials and observational cohorts reported higher rates of virological suppression after highly active antiretroviral therapy (HAART) including efavirenz (EFV), compared with boosted protease inhibitors (PIs). Correlations with immunological and clinical outcomes are unclear. Patients of the Italian MASTER cohort who started HAART from 2000 to 2010 were selected. Outstanding outcome (composite outcome for success (COS)) was introduced. We evaluated predictors of COS (no AIDS plus CD4+ count >500/ mm3 plus HIV-RNA <500 copies/mL) and of eight single outcomes either at month 6 or at year 3. Multivariable logistic regression was conducted. There were 6259 patients selected. Patients on EFV (43%) were younger, had greater CD4+ count, presented with AIDS less frequently, and more were Italians. At year 3, 90% of patients had HIV RNA <500 copies/mL, but only 41.4% were prescribed EFV, vs. 34.1% prescribed boosted PIs achieved COS (p <0.0001). At multivariable analysis, patients on lopinavir/ritonavir had an odds ratio of 0.70 for COS at year 3 (p <0.0001). Foreign origin and positive hepatitis C virus-Ab were independently associated with worse outcome (OR 0.54, p <0.0001 and OR 0.70, p 0.01, respectively). Patients on boosted PIs developed AIDS more frequently either at month 6 (13.8% vs. 7.6%, p <0.0001) or at year 3 (17.1% vs. 13.8%, p <0.0001). At year 3, deaths of patients starting EFV were 3%, vs. 5% on boosted PIs (p 0.008). In this study, naïve patients on EFV performed better than those on boosted PIs after adjustment for imbalances at baseline. Even when virological control is achieved, COS is relatively rare. Hepatitis C virus-positive patients and those of foreign origin are at risk of not obtaining COS. Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved

    Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study

    Get PDF
    Peer reviewe

    Il drenaggio nelle anastomosi colonrettali basse. Analisi di una esperienza clinica.

    No full text

    Impiego in elezione della colostomia di protezione nella chirurgia resettiva del retto.

    No full text
    To clarify the indications and clinical value of "protective colostomy" in cases of low colorectal anastomoses, some recent series are analyzed and compared to the experience of the authors, which includes 65 low anterior resections of the rectum for cancer, with colorectal anastomosis at less than 10 cm from the anus. "Protective colostomy" seems not to prevent the onset of anastomotic fistulae, but appears effective in reducing its clinical effects. "Protective colostomy" seems convenient when there is an increased risk of fistulization, as indicated by a series of factors defined by the authors. In doubtful cases "protective colostomy" may be performed but not opened. So the patient will be given the maximum safety, and not submitted to the uneasiness of an open colostomy unless needed
    corecore